Vadocaine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341367

CAS#: 72005-58-4

Description: Vadocaine is a biochemical.


Price and Availability

Size
Price

Size
Price

Size
Price

Vadocaine is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 341367
Name: Vadocaine
CAS#: 72005-58-4
Chemical Formula: C18H28N2O2
Exact Mass: 304.2151
Molecular Weight: 304.434
Elemental Analysis: C, 71.02; H, 9.27; N, 9.20; O, 10.51


Synonym: Vadocaine; Vadocainum; Vadocaina.

IUPAC/Chemical Name: (+-)-6'-Methoxy-2-methyl-1-piperidinepropiono-2',4'-xylidide

InChi Key: UJCARUGFZOJPMI-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H28N2O2/c1-13-11-14(2)18(16(12-13)22-4)19-17(21)8-10-20-9-6-5-7-15(20)3/h11-12,15H,5-10H2,1-4H3,(H,19,21)

SMILES Code: Cc1cc(c(c(c1)OC)NC(=O)CCN2CCCCC2C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Karttunen P, Silvasti M, Virta P, Saano V, Nuutinen J. The effects of vadocaine, dextromethorphan, diphenhydramine and hydroxyzine on the ciliary beat frequency in rats in vitro. Pharmacol Toxicol. 1990 Aug;67(2):159-61. PubMed PMID: 2255670.

2: Silvasti M, Karttunen P, Tukiainen H, Mykkänen M, Ottoila P. Steady state pharmacokinetics of the new antitussive compound vadocaine hydrochloride. Arzneimittelforschung. 1990 Apr;40(4):453-6. PubMed PMID: 2357246.

3: Silvasti M, Karttunen P, Tukiainen H, Mykkänen M, Hänninen U, Välttilä S. The single dose and steady-state pharmacokinetics of a vadocaine tablet in healthy human volunteers. Int J Clin Pharmacol Ther Toxicol. 1989 Nov;27(11):558-63. PubMed PMID: 2613390.

4: Karttunen P, Uusitupa M, Helin M, Tukiainen H, Silvasti M. Assessment of the safety margin of vadocaine hydrochloride in man. Arzneimittelforschung. 1988 Apr;38(4A):642-6. PubMed PMID: 3395404.

5: Karttunen P. Assessment of the antitussive effect of vadocaine hydrochloride using citric acid-induced cough in healthy volunteers. Arzneimittelforschung. 1988 Apr;38(4A):639-41. PubMed PMID: 3395403.

6: Karttunen P, Männistö PT, Tukiainen H, Uusitupa M, Nissinen E. Pharmacokinetics of graded single doses of the novel antitussive compound vadocaine hydrochloride in healthy male volunteers. Arzneimittelforschung. 1988 Apr;38(4A):635-8. PubMed PMID: 3395402.

7: Karttunen P, Tukiainen H, Uusitupa M, Männistö PT. First human studies on the safety and antitussive activity of vadocaine hydrochloride. Arzneimittelforschung. 1988 Apr;38(4A):631-4. PubMed PMID: 3395401.

8: Vuorela A, Mäntylä R, Männistö PT. Tissue distribution of the novel antitussive compound vadocaine hydrochloride in white female mice studied by whole-body autoradiography. Arzneimittelforschung. 1988 Apr;38(4A):628-30. PubMed PMID: 3395400.

9: Mäntylä R, Männistö PT, Vuorela A, Nissinen E. Preliminary pharmacokinetics of the new antitussive compound vadocaine hydrochloride in animals. Arzneimittelforschung. 1988 Apr;38(4A):624-7. PubMed PMID: 3395399.

10: Etemadzadeh E, Ahtee L, Männistö PT. Comparative studies on the dependence liability of morphine hydrochloride, codeine phosphate and two novel antitussive compounds vadocaine hydrochloride and N-(2',4'-dimethyl-6'-methoxyphenyl)-4-(diethylamine) butanamide hydrochloride in mice. Arzneimittelforschung. 1988 Apr;38(4A):620-3. PubMed PMID: 3395398.

11: Paakkari I, Svartström-Fraser M. Cardiovascular and ventilator effects of vadocaine hydrochloride in urethane-anaesthetized rats and guinea-pigs. Arzneimittelforschung. 1988 Apr;38(4A):617-9. PubMed PMID: 3395397.

12: Salonen RO. Comparison of the effects of two opioid antitussives, vadocaine hydrochloride, clobutinol and lidocaine on lung mechanics in guinea-pigs. Arzneimittelforschung. 1988 Apr;38(4A):609-12. PubMed PMID: 3395396.

13: Karttunen P, Männistö PT, Lahovaara S, Havas A. Studies on the nonspecific central nervous system effects of the novel antitussive compound vadocaine hydrochloride. Arzneimittelforschung. 1988 Apr;38(4A):605-8. PubMed PMID: 3395395.

14: Männistö PT, Karttunen P, Lahovaara S, Nissinen E, Davies JE, Algate DR, Baines MW. Antitussive action of the new anilide derivative vadocaine hydrochloride compared with codeine phosphate in four animal models. Arzneimittelforschung. 1988 Apr;38(4A):598-604. PubMed PMID: 3395394.

15: Vadocaine hydrochloride. A novel antitussive compound. Arzneimittelforschung. 1988 Apr;38(4A):597-646. PubMed PMID: 3395393.

16: Kangasaho M. Effects of lidocaine, codeine and vadocaine hydrochloride on platelet aggregation in human platelet-rich plasma. Arzneimittelforschung. 1988 Apr;38(4A):613-6. PubMed PMID: 2840087.

17: Hanhijärvi H, Voipio HM, Huuskonen H, Männistö P, Nevalainen T. Experimental compound OR-K-242-HCl an anilide derivative slows conduction velocity of the heart in the conscious beagle dog. Arch Toxicol Suppl. 1986;9:213-6. PubMed PMID: 3468900.